Close Menu

NEW YORK (GenomeWeb) – Premaitha Health said today that it plans to raise approximately £2.5 million ($3.3 million) through a fast offering of ordinary shares, a so-called accelerated bookbuild, that will proceed in two tranches. It is offering the shares at a price of 10 pence per ordinary share, which represents a discount of 19 percent to the closing price on September 27.

The first tranche of shares will be allotted on Oct. 4 and the second tranche on Oct. 25.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.